Industry

OT166 is a potential first-in-class non-invasive selective RGD integrin inhibitor, delivered as eye drop, for the treatment of diabetic retinopathy OT166 has the potential to address an unmet need for an earlier, non-invasive ophthalmic treatment for diabetic retinopathy BOSTON–(BUSINESS WIRE)–OcuTerra Therapeutics, Inc. (“OcuTerra”), a clinical stage ophthalmology company developing innovative drugs to treat ophthalmic diseases … [Read more…]

CAMBRIDGE, Mass.–(BUSINESS WIRE)–Aura Biosciences, Inc. (NASDAQ: AURA), a clinical-stage biotechnology company developing a novel class of virus-like drug conjugate (VDC) therapies for multiple oncology indications, today announced that Elisabet de los Pinos, PhD, Chief Executive Officer, and Julie Feder, Chief Financial Officer, of Aura will participate in a fireside chat at the 2022 Hybrid BTIG … [Read more…]

LEWISVILLE, Texas–(BUSINESS WIRE)–Orthofix Medical Inc. (NASDAQ:OFIX), a global medical device company with a spine and orthopedics focus, today announced a strategic partnership agreement with CGBio, a developer of innovative, synthetic bone grafts currently used clinically in Asia for spine, orthopedic, trauma and dental applications. The two companies will work together for clinical development and commercialization … [Read more…]

Total revenues increased 29% year-over-year (Y/Y) to $911 million; total product revenues of $664 million (+15% Y/Y) Jakafi® (ruxolitinib) net product revenues of $598 million in Q2’22 (+13% Y/Y) driven by volume growth; raising the bottom end of full year guidance to new range of $2.36 to $2.40 billion Opzelura™ (ruxolitinib) cream approved as first … [Read more…]

Subjects with Long COVID receiving AXA1125 experienced a clinically and statistically significant improvement in mental (p=0.0097) and physical (p=0.0097) fatigue scores compared to placebo subjects Responders to AXA1125 demonstrated significantly improved scores during a 6 minute walk test No emergent adverse events (AEs) or serious adverse events (SAEs) occurred Regulatory meetings are planned to discuss … [Read more…]

DUBLIN–(BUSINESS WIRE)–The “Fertility Drugs Global Market Report 2022, Gender, Route of Administration, Type Of Drug, Distribution Channel” report has been added to ResearchAndMarkets.com’s offering. The global fertility drugs market is expected to grow from $2.77 billion in 2021 to $2.92 billion in 2022 at a compound annual growth rate (CAGR) of 5.4%. The growth is … [Read more…]

DUBLIN–(BUSINESS WIRE)–The “Asia Pacific Healthcare Technology Management Market Size, Share & Industry Trends Analysis Report By Type of Services, By Facility Type, By Country and Growth Forecast, 2022 – 2028” report has been added to ResearchAndMarkets.com’s offering. The Asia Pacific Healthcare Technology Management Market is expected to witness market growth of 11.4% CAGR during the … [Read more…]

DUBLIN–(BUSINESS WIRE)–The “In Vitro Diagnostics (IVD) Quality Controls: Global Market” report has been added to ResearchAndMarkets.com’s offering. Report Scope The current report provides detailed information regarding the in vitro diagnostics quality controls market. This report highlights the current and future market potential of in vitro diagnostics controls and a detailed analysis of the drivers and … [Read more…]

DUBLIN–(BUSINESS WIRE)–The “Liver Cancer – Pipeline Insight, 2022” clinical trials has been added to ResearchAndMarkets.com’s offering. This Liver Cancer – Pipeline Insight, 2022 report provides comprehensive insights about 75+ companies and 75+ pipeline drugs in Liver Cancer pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the … [Read more…]

TRIESENBERG, Liechtenstein–(BUSINESS WIRE)–#Artilysin–Lysando AG – market leader in the field of antimicrobial proteins – is pleased to announce that Wilhelm von Haller has joined the team as Chief Financial Officer this March. Baron von Haller is an expert in Corporate Finance, apprenticed during more than 30 years as leading executive in various roles at Deutsche … [Read more…]